NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 250 Massachusetts Ave. Cambridge, MA 02139 September 30, 2015Secured Note Agreement • November 6th, 2015 • XOMA Corp • Pharmaceutical preparations
Contract Type FiledNovember 6th, 2015 Company IndustryReference is made to that certain Secured Note Agreement, dated May 26, 2005, as amended (the “Note”), between XOMA (US) LLC, a Delaware limited liability company (“XOMA”), and Novartis Vaccines and Diagnostics, Inc. (f/k/a Chiron Corporation), a Delaware corporation (“NVDI”), which was assigned by NVDI to Novartis Institutes for BioMedical Research, Inc. (“NIBR”) with XOMA’s consent immediately prior to the execution of this letter agreement.
ContractResearch, Development and Commercialization Agreement • November 6th, 2015 • XOMA Corp • Pharmaceutical preparations
Contract Type FiledNovember 6th, 2015 Company Industry[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
LICENSE AGREEMENT by and between XOMA (US) LLC and NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.License Agreement • November 6th, 2015 • XOMA Corp • Pharmaceutical preparations • New York
Contract Type FiledNovember 6th, 2015 Company Industry JurisdictionThis LICENSE AGREEMENT (the “Agreement”) is entered into and made effective as of the 30th day of September, 2015 (the “Effective Date”) by and between XOMA (US) LLC, a limited liability company organized under the laws of Delaware having offices at 2910 Seventh Street, Berkeley, California (“XOMA”), and Novartis International Pharmaceutical Ltd., a company organized under the laws of Bermuda having offices at 131 Front Street, Hamilton, HM 12, Bermuda (“Novartis”). XOMA and Novartis are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”